Charles Pritchard

Learn More
OBJECTIVE To assess safety and clinical outcomes in patients with inflammatory arthritis after intraarticular (IA) injection of rAAV2-TNFR:Fc, a recombinant adeno-associated viral vector containing the human tumor necrosis factor (TNF) receptor-immunoglobulin (IgG1) Fc fusion (TNFR:Fc) gene. METHODS In this phase 1/2 randomized study, adults with(More)
The safety of other biologic therapies in rheumatoid arthritis (RA) following B cell-depletion therapy with rituximab has not been established. This retrospective chart review of patients attending an outpatient rheumatology clinic aimed to assess the incidence of adverse events in patients receiving biologic agents to treat RA after an inadequate response(More)
OBJECTIVE To determine if changes in biomarkers of inflammation and bone turnover in response to treatment with infliximab plus methotrexate (MTX) versus MTX alone are associated with improvement in clinical measures of signs, symptoms, and structural damage in early rheumatoid arthritis. METHODS Sera were collected from patients in the ASPIRE study who(More)
BACKGROUND As recommended in the current prescribing information, rituximab infusions in patients with rheumatoid arthritis (RA) take 4.25 hours for the first infusion and 3.25 hours for subsequent infusions, which is a burden on patients and the health care system. We therefore evaluated the safety of infusing rituximab at a faster rate for an infusion(More)
We investigated the frequency of patellar tendon rupture in our patients with systemic lupus erythematosus (SLE) in order to characterize the features that might predict rupture and compared our experience to that described in the literature. Four of 180 patients with lupus seen in the last 10 years had patellar tendon rupture. Duration of disease ranged(More)
  • 1